Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) represent a major advance in cancer treatment. The lowered immune tolerance induced by ICIs brought to light a series of immune-related adverse events (irAEs). Pembrolizumab belongs to the ICI class and is a humanized IgG4 anti-PD-1 antibody that blocks the intera...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannini, Elena, Bonasoni, Maria Paola, D’Aleo, Michele, Tamagnini, Ione, Tudini, Matteo, Fais, Paolo, Pelotti, Susi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342066/
https://www.ncbi.nlm.nih.gov/pubmed/37446095
http://dx.doi.org/10.3390/ijms241310919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342066/
https://www.ncbi.nlm.nih.gov/pubmed/37446095
http://dx.doi.org/10.3390/ijms241310919

Ejemplares similares